Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cefepime microbiologic profile and update.

R E Kessler1

  • 1Bristol-Myers Squibb Co, Wallingford, CT, USA.

The Pediatric Infectious Disease Journal
|April 17, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and characterization of cell wall-cell division gene clusters in pathogenic gram-positive cocci.

Journal of bacteriology·1997
Same author

Perspectives on chemotherapeutic approaches to antibiotic-resistant bacteria.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1997
Same author

Direct quantitation of the number of individual penicillin-binding proteins per cell in Escherichia coli.

Journal of bacteriology·1996
Same author

Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·1996
Same author

Susceptibility of bacterial isolates to beta-lactam antibiotics from U.S. clinical trials over a 5-year period.

The American journal of medicine·1996
Same author

Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Antimicrobial agents and chemotherapy·1996
Same journal

Phase 2/3, Open-label, Randomized, Active-controlled Clinical Trial Evaluating the Safety and Efficacy of Imipenem/Cilastatin/Relebactam in Pediatric Patients From Birth to Less Than 18 Years With Gram-negative Bacterial Infections.

The Pediatric infectious disease journal·2026
Same journal

Determinants of Severity in Pediatric Viral Lower Respiratory Tract Diseases From Emergency Department Presentation to Hospital Course.

The Pediatric infectious disease journal·2026
Same journal

Oropharyngeal Colonization by Kingella kingae and Septic Arthritis in Children 6-48 Months of Age: A Portuguese Multicenter Case-control Study.

The Pediatric infectious disease journal·2026
Same journal

Trends in Late-onset Sepsis in Very Low Birth Weight Preterm Infants in the Brazilian Network on Neonatal Research: A 10-year Cohort Study.

The Pediatric infectious disease journal·2026
Same journal

Severe Mycoplasma-induced Rash and Mucositis Mimicking Stevens-Johnson Syndrome Treated With Steroid Pulse Therapy: A Case Highlighting Diagnostic Challenges and Therapeutic Considerations.

The Pediatric infectious disease journal·2026
Same journal

Clindamycin Prophylaxis in Pediatric Punctate Outer Retinal Toxoplasmosis.

The Pediatric infectious disease journal·2026
See all related articles

Cefepime, a fourth-generation cephalosporin antibiotic, shows improved activity against Gram-negative bacteria and offers broad-spectrum coverage for pediatric infections. Its unique structure enhances bacterial membrane penetration and beta-lactamase stability.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Cephalosporin antibiotics have evolved, leading to new generations with enhanced antibacterial properties.
  • Cefepime represents a key advancement as a fourth-generation cephalosporin.

Purpose of the Study:

  • To comprehensively review the microbiological profile of cefepime.
  • To evaluate cefepime's efficacy against common pediatric pathogens.

Main Methods:

  • Review of existing literature on cefepime's chemical structure and properties.
  • Analysis of in vitro activity data against a range of bacterial pathogens.
  • Comparison of cefepime's spectrum of activity with third-generation cephalosporins.

Main Results:

Related Experiment Videos

  • Cefepime's zwitterionic nature facilitates faster penetration of Gram-negative bacterial outer membranes.
  • Enhanced stability against beta-lactamases compared to third-generation cephalosporins.
  • Demonstrated in vitro activity against key pediatric pathogens, including Pseudomonas aeruginosa and resistant Enterobacteriaceae, with Gram-positive coverage comparable to cefotaxime and ceftriaxone.

Conclusions:

  • Cefepime's broad spectrum of activity makes it a valuable therapeutic option.
  • Effective for treating pediatric infections caused by susceptible bacterial pathogens.